Tivorsan Makes Key DMD Therapy Development

Rhode Island-based Tivorsan Pharmaceuticals has reported promising results of their investigational peptide drug on muscle function in an animal model of Duchenne Muscular Dystrophy (DMD). Encouraged by these finding, Tivorsan is gearing up to begin clinical trials of the recombinant human biglycan therapeutic in DMD patients. Given its purported muscle enhancing effects, this drug may also be a potential ALS therapeutic.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail